Home/Pipeline/Severe Covid

Severe Covid

Severe COVID-19

DiscoveryActive

Key Facts

Indication

Severe COVID-19

Phase

Discovery

Status

Active

Company

Genclis

About Genclis

Genclis is a biotechnology company pioneering a novel drug discovery and development platform based on Transcription Infidelity (TI), a biological mechanism that generates immunologically active variant proteins from mRNA. Its pipeline includes programs in veterinary and human allergies, severe COVID-19, Type 1 Diabetes, and Lou Gehrig's disease (ALS), with its veterinary allergy candidate appearing most advanced. The company is privately held, led by co-founder and CEO Bernard Bihain, and operates with a cautious, capital-efficient business model focused on robust preclinical de-risking before clinical advancement.

View full company profile

Therapeutic Areas

Allergy Infectious Disease Autoimmune Disease Neurodegenerative Disease

Other Severe COVID-19 Drugs

Drug	Company	Phase	Status
SCN-101 (COVID-19 hIVIG)	Scinai Immunotherapeutics	Phase 2/3	Completed
Exvastat Program	Numedicus	Phase 2	Active
CSL324	CSL	Phase 3	Active (EUA granted)